Status and phase
Conditions
Treatments
About
This is a Phase II study is being done to determine whether a new combination of therapies is safe and effective for adults to treat Melanoma before surgery. The two therapies that will be combined in this study are nivolumab and RP2.
Nivolumab is a standard treatment for this type of cancer. Nivolumab targets and blocks a receptor called PD-1 on the surface of certain immune cells called T-cells. Blocking PD-1 may activate T-cells to find and kill cancer cells.
RP2 is a new treatment that is not yet FDA approved to treat this cancer. RP2 is a herpes simplex virus (a microscopic life form commonly known as the "cold sore virus") that has been changed in the laboratory to grow in and destroy cancer cells and to activate (turn on) the immune system to attack the cancer cells.
Full description
This single-arm Phase II study will evaluate the safety and efficacy of neoadjuvant RP2 in combination with nivolumab in adults with resectable advanced melanoma. Participants will receive RP2 and nivolumab prior to surgery, followed by adjuvant nivolumab after surgery. The study will assess pathologic response at surgery, treatment-related toxicity, tumor response, recurrence-free survival, and overall survival. Exploratory analyses will evaluate changes in immune and tumor biomarkers associated with treatment response.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Be willing and able to provide written informed consent for the trial.
Be ≥ 18 years of age on day of signing informed consent.
Cytologically or histologically confirmed resectable stage IIIB, IIIC, IIID, or IV melanoma of cutaneous or unknown primary origin with one or more macroscopic lymph node metastases (clinically detectable), that can be biopsied and a maximum of 3 additional resectable in-transit metastases. A concurrent resectable primary melanoma is allowed. Clinical detectable lymph nodes are defined as either a palpable node ora non-palpable but enlarged lymph node according to RECISTv1.1 (at least 15 mm in short axis).
At least one measurable lesion per RECIST v1.1; the injected lesion may also serve as the target lesion.
Anti-PD-1 therapy naïve, or if previously treated with immunotherapy, recurrence occurred at least 12 weeks after the last dose of therapy.
Females of childbearing potential must have a negative beta-human chorionic gonadotropin (β- hCG) test during screening, and a negative urine pregnancy test on days of treatment with RP2 and/or nivolumab. Female subjects are considered to be of childbearing potential unless one of the following criteria is met:
a. Permanent sterilization (hysterectomy, bilateral salpingectomy, or bilateral oophorectomy) or documented postmenopausal status (defined as 12 months of amenorrhea in a woman > 45 years-of-age in the absence of other biological or physiological causes). Note: Documentation may include review of medical records, medical examination, or medical history interview by study site staff.
Sexually active fertile subjects and their partners must agree to use highly effective methods of contraception prior to study entry, during the course of the study, and for 90 days after the last dose of RP2 alone or 5 months after the last dose of nivolumab. An additional contraceptive method, such as a barrier method (e.g., condom), is required. In addition, men must agree not to donate sperm and women must agree not to donate eggs (ova, oocyte) for the purpose of reproduction during these same periods.
a. Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject.
Have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) Performance Scale.
Demonstrate adequate organ function. All screening labs should be performed within 28 days of treatment initiation. Baseline labs may be used as screening -
Exclusion criteria
Prior treatment with an oncolytic virus therapy.
Active significant herpetic infections or prior complications of HSV-1 infection (e.g., herpetic keratitis or encephalitis).
Immunodeficiency or use of systemic corticosteroids exceeding 10 mg of prednisone daily (or equivalent). Steroids for physiologic repletion (for example hydrocortisone for adrenal insufficiency) are permitted.
Has acute or chronic active hepatitis B and C virus infection or known history of untreated hepatitis B (defined as hepatitis B surface antigen [HBsAg] reactive) or known active hepatitis C virus (HCV) (defined as HCV RNA [qualitative]) or HIV infection (see note).
Had systemic infection requiring IV antibiotics or other serious infection within 14 days prior to dosing.
Major surgery ≤ 1 week prior to starting study drug. Note: Patients who undergo major surgery must adequately recover prior to starting study treatment.
Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within four weeks prior to the first dose of study treatment.
History of documented allergic reactions or acute hypersensitivity reactions attributed to RP2 or any of its excipients.
Has received a live vaccine within 30 days prior to the first dose of study drug. Examples of live vaccines include, but are not limited to measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacille Calmette-Guérin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed, however, intranasal influenza vaccines (e.g., FluMist®) are live attenuated vaccines and are not allowed.
a. Note: Available COVID-19 vaccines do not contain live virus.
Has a history or current evidence of any condition, therapy, or laboratory abnormality that:
Has serious or uncontrolled medical disorders that do not make it in the best interest of the patient to participate, in the opinion of the treating Investigator.
Has known psychiatric, alcohol abuse, or substance abuse disorders that would in the opinion of the treating investigator interfere with cooperating with the requirements of the study.
Is a person deprived of their liberty by a judicial or administrative decision, or an adult person subject to a legal protection measure.
Is a solid organ transplant recipient.
Patients with tumors that are located near critical structures, such as the carotid artery or portal vein, or scalp lesions presenting with moderate to extensive bone erosion and tumors that may have invaded the heart, great vessels, or other critical structures will not be eligible because these areas should not be injected. Injection through an ulcerated area of a lesion should be avoided.
Known additional malignancy that is progressing or requires active treatment (patients with definitively treated malignancies and low risk of recurrence, or patients with low risk of progression (such as indolent lymphomas) may be eligible after discussion with the PI).
Active or untreated central nervous system (CNS) metastases.
Active autoimmune disease requiring systemic therapy within the past 2 years, not including endocrinopathies or vitiligo.
History of non-infectious pneumonitis or interstitial lung disease.
Clinically significant hemoptysis or tumor-associated bleeding within 2 weeks prior to study treatment initiation.
Clinically significant cardiovascular disease (i.e., including myocarditis or congestive heart failure (defined as New York Heart Association Functional Classification III or IV), or unstable angina, serious uncontrolled cardiac arrhythmia, cerebral vascular accident, or myocardial infarction within 6 months of treatment.).
Use of anti-coagulation medication that cannot be held, at the discretion of the treating investigator, for the baseline biopsy and for surgical resection.
Primary purpose
Allocation
Interventional model
Masking
34 participants in 1 patient group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal